{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T11:04:27Z","timestamp":1785323067028,"version":"3.55.0"},"reference-count":264,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:00:00Z","timestamp":1785283200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:p>Immune checkpoint inhibitors (ICIs) have transformed the treatment landscape across a broad range of malignancies by restoring antitumor immunity through blockade of key inhibitory immune pathways, including programmed death receptor-1 (PD-1), programmed death ligand-1 (PD-L1), and cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4). Yet the same widespread immune activation that drives their therapeutic benefit renders patients susceptible to immune-related adverse events (irAEs). Among these cardiovascular toxicities have emerged as a particularly critical concern, drawing growing attention within the evolving field of cardio-oncology. ICI-associated cardiotoxicity encompasses a broad clinical spectrum, ranging from myocarditis and pericarditis to arrhythmias, heart failure, and vascular complications. Of these, immune-mediated myocarditis is the most severe, carrying a disproportionately high mortality risk despite its relatively low incidence. Its pathophysiology is multifaceted, driven by dysregulated immune activation, myocardial inflammation, T-cell-mediated cytotoxicity, aberrant cytokine release, and molecular mimicry between tumor and cardiac antigens. Additional mechanisms\u2014including B-cell activation, complement cascade signaling, and inflammasome pathway engagement\u2014may further amplify myocardial injury and heighten arrhythmogenic susceptibility. In this review, we summarize current insights into the immunological mechanisms underlying ICI-induced cardiotoxicity and examined the expanding clinical spectrum of cardiovascular irAEs. We further discuss strategies for early detection, risk stratification, and clinical surveillance, encompassing biomarker monitoring and multimodal imaging. Emerging therapeutic strategies targeting implicated immune pathways are also being explored to mitigate cardiovascular complications without compromising anticancer efficacy. A deeper mechanistic understanding will be essential for advancing the prevention, diagnosis, and management of ICI-associated cardiovascular toxicity in oncology practice.<\/jats:p>","DOI":"10.3389\/fcvm.2026.1872588","type":"journal-article","created":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T10:35:19Z","timestamp":1785321319000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Immune checkpoint inhibitor-induced cardiotoxicity: from immune mechanisms to clinical surveillance and targeted therapies"],"prefix":"10.3389","volume":"13","author":[{"given":"Nathan K.","family":"Chen","sequence":"first","affiliation":[{"name":"Institute of Molecular Medicine, UTHealth-McGovern Medical School","place":["Houston, TX, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn D.","family":"Hok","sequence":"additional","affiliation":[{"name":"Institute of Molecular Medicine, UTHealth-McGovern Medical School","place":["Houston, TX, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narsi","family":"Chokshi","sequence":"additional","affiliation":[{"name":"Institute of Molecular Medicine, UTHealth-McGovern Medical School","place":["Houston, TX, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Shadid","sequence":"additional","affiliation":[{"name":"Institute of Molecular Medicine, UTHealth-McGovern Medical School","place":["Houston, TX, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haydn E.","family":"Rich","sequence":"additional","affiliation":[{"name":"Institute of Molecular Medicine, UTHealth-McGovern Medical School","place":["Houston, TX, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lavanya","family":"Gunamalai","sequence":"additional","affiliation":[{"name":"Institute of Molecular Medicine, UTHealth-McGovern Medical School","place":["Houston, TX, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Francoise","family":"Doursout","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, UTHealth-McGovern Medical School","place":["Houston, TX, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nirmal K.","family":"Banda","sequence":"additional","affiliation":[{"name":"Division of Rheumatology-Department of Medicine, School of Medicine, University of Colorado Anschutz Medical Campus","place":["Aurora, CO, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pooja","family":"Shivshankar","sequence":"additional","affiliation":[{"name":"Institute of Molecular Medicine, UTHealth-McGovern Medical School","place":["Houston, TX, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1163633","DOI":"10.3389\/fimmu.2023.1163633","article-title":"The role of PD-1 signaling in health and immune-related diseases","volume":"14","author":"Chen","year":"2023","journal-title":"Front Immunol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1198365","DOI":"10.3389\/fimmu.2023.1198365","article-title":"Current understanding of CTLA-4: from mechanism to autoimmune diseases","volume":"14","author":"Hossen","year":"2023","journal-title":"Front Immunol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41419-023-06389-5","article-title":"Mechanisms of immune checkpoint inhibitors: insights into the regulation of circular RNAS involved in cancer hallmarks","volume":"15","author":"Meng","year":"2024","journal-title":"Cell Death Dis"},{"key":"B4","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1186\/s40001-024-01901-9","article-title":"Targeting cytotoxic lymphocyte antigen 4 (CTLA-4) in breast cancer","volume":"29","author":"Jama","year":"2024","journal-title":"Eur J Med Res"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1080\/21645515.2015.1129478","article-title":"Ipilimumab (anti-ctla-4 mab) in the treatment of metastatic melanoma: effectiveness and toxicity management","volume":"12","author":"Savoia","year":"2016","journal-title":"Hum Vaccin Immunother"},{"key":"B6","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1186\/s12885-025-15521-x","article-title":"Efficacy and safety of PD-1\/PD-L1 inhibitors plus chemotherapy in breast cancer: a systematic review and meta-analysis with focus on triple-negative subtype and immune-related adverse events","volume":"26","author":"Aikelaimu","year":"2026","journal-title":"BMC Cancer"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1111\/1759-7714.13060","article-title":"Efficacy of PD-1\/PD-L1 inhibitors in patients with advanced non-small cell lung cancer: a meta-analysis of randomized clinical trials","volume":"10","author":"Peng","year":"2019","journal-title":"Thorac Cancer"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14041200","article-title":"Advancements in melanoma treatment: a review of PD-1 inhibitors, T-VEC, mRNA vaccines, and tumor-infiltrating lymphocyte therapy in an evolving landscape of immunotherapy","volume":"14","author":"Mehta","year":"2025","journal-title":"J Clin Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.jaccao.2022.09.004","article-title":"Immune checkpoint inhibitor therapy in oncology: current uses and future directions: JACC: cardioOncology state-of-the-art review","volume":"4","author":"Tan","year":"2022","journal-title":"JACC CardioOncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11071878","article-title":"LAG-3 Inhibitors: novel immune checkpoint inhibitors changing the landscape of immunotherapy","volume":"11","author":"Ibrahim","year":"2023","journal-title":"Biomedicines"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol32040230","article-title":"LAG3, TIM3 and TIGIT: new targets for immunotherapy and potential associations with radiotherapy","volume":"32","author":"Mirestean","year":"2025","journal-title":"Curr Oncol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1340373","DOI":"10.3389\/fimmu.2024.1340373","article-title":"Immune checkpoint inhibitors associated cardiovascular immune-related adverse events","volume":"15","author":"Jo","year":"2024","journal-title":"Front Immunol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"e032620","DOI":"10.1161\/JAHA.123.032620","article-title":"Immune checkpoint inhibitors and cardiotoxicity: a comparative meta-analysis of observational studies and randomized controlled trials","volume":"13","author":"Sharma","year":"2024","journal-title":"J Am Heart Assoc"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-006398","article-title":"Society for immunotherapy of cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) terminology","volume":"11","author":"Naidoo","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B15","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: aSCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1001\/jamaoncol.2024.3065","article-title":"Immune checkpoint inhibitor-induced cardiotoxicity: a systematic review and meta-analysis","volume":"10","author":"Nielsen","year":"2024","journal-title":"JAMA Oncol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"103257","DOI":"10.1016\/j.cpcardiol.2025.103257","article-title":"Balancing hope and heart: an umbrella review of cardiotoxicity in immune checkpoint inhibitor cancer therapies","volume":"51","author":"Sethi","year":"2026","journal-title":"Curr Probl Cardiol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1016\/S1470-2045(18)30608-9","article-title":"Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational study","volume":"19","author":"Salem","year":"2018","journal-title":"Lancet Oncol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1182\/blood-2008-12-195792","article-title":"Tumor antigen-specific CD8T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired","volume":"114","author":"Ahmadzadeh","year":"2009","journal-title":"Blood"},{"key":"B20","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1084\/jem.20061496","article-title":"PD-1 is a regulator of virus-specific CD8+ T cell survival in HIV infection","volume":"203","author":"Petrovas","year":"2006","journal-title":"J Exp Med"},{"key":"B21","doi-asserted-by":"publisher","first-page":"155932","DOI":"10.1016\/j.cyto.2022.155932","article-title":"PD-1 inhibitor induces myocarditis by reducing regulatory T cells, activating inflammatory responses, promoting myocardial apoptosis and autophagy","volume":"157","author":"Liu","year":"2022","journal-title":"Cytokine"},{"key":"B22","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.molimm.2008.10.007","article-title":"The B7 family of immunoregulatory receptors: a comparative and evolutionary perspective","volume":"46","author":"Hansen","year":"2009","journal-title":"Mol Immunol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1084\/jem.192.7.1027","article-title":"Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation","volume":"192","author":"Freeman","year":"2000","journal-title":"J Exp Med"},{"key":"B24","doi-asserted-by":"publisher","first-page":"12293","DOI":"10.1073\/pnas.192461099","article-title":"Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade","volume":"99","author":"Iwai","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B25","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1126\/science.291.5502.319","article-title":"Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice","volume":"291","author":"Nishimura","year":"2001","journal-title":"Science"},{"key":"B26","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1038\/nm730","article-title":"Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion","volume":"8","author":"Dong","year":"2002","journal-title":"Nat Med"},{"key":"B27","doi-asserted-by":"publisher","first-page":"2062","DOI":"10.1161\/CIRCULATIONAHA.107.709360","article-title":"Endothelial programmed death-1 ligand 1 (PD-L1) regulates CD8+ T-cell mediated injury in the heart","volume":"116","author":"Grabie","year":"2007","journal-title":"Circulation"},{"key":"B28","doi-asserted-by":"publisher","first-page":"4876","DOI":"10.4049\/jimmunol.1200389","article-title":"PD-1 protects against inflammation and myocyte damage in T cell-mediated myocarditis","volume":"188","author":"Tarrio","year":"2012","journal-title":"J Immunol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1084\/jem.20100466","article-title":"PD-1 and LAG-3 inhibitory co-receptors act synergistically to prevent autoimmunity in mice","volume":"208","author":"Okazaki","year":"2011","journal-title":"J Exp Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21072399","article-title":"Programmed cell death-1: programmed cell death-ligand 1 interaction protects human cardiomyocytes against T-cell mediated inflammation and apoptosis response in vitro","volume":"21","author":"Tay","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B31","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.cca.2014.12.007","article-title":"Interferon-gamma in foam cell formation and progression of atherosclerosis","volume":"441","author":"Yu","year":"2015","journal-title":"Clin Chim Acta"},{"key":"B32","doi-asserted-by":"publisher","first-page":"2458","DOI":"10.1093\/cvr\/cvad068","article-title":"An interferon gamma response signature links myocardial aging and immunosenescence","volume":"119","author":"Ashour","year":"2023","journal-title":"Cardiovasc Res"},{"key":"B33","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/s44161-024-00447-7","article-title":"The PD-1-PD-L1 pathway maintains an immunosuppressive environment essential for neonatal heart regeneration","volume":"3","author":"Vargas Aguilar","year":"2024","journal-title":"Nat Cardiovasc Res"},{"key":"B34","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1038\/s41598-024-85065-w","article-title":"PD-L1 monoclonal antibody alleviated MI injury of left ventricular function via modulating CD47\/SHP2\/SIRPalpha\/SYK\/FcgammaR signalings in tumor associated macrophages","volume":"15","author":"Kong","year":"2025","journal-title":"Sci Rep"},{"key":"B35","doi-asserted-by":"publisher","first-page":"9543","DOI":"10.1128\/MCB.25.21.9543-9553.2005","article-title":"CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms","volume":"25","author":"Parry","year":"2005","journal-title":"Mol Cell Biol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1126\/science.1202947","article-title":"Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4","volume":"332","author":"Qureshi","year":"2011","journal-title":"Science"},{"key":"B37","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1126\/science.1160062","article-title":"CTLA-4 control over Foxp3\u2009+\u2009regulatory T cell function","volume":"322","author":"Wing","year":"2008","journal-title":"Science"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.4049\/jimmunol.1200972","article-title":"Cutting edge: cell-extrinsic immune regulation by CTLA-4 expressed on conventional T cells","volume":"189","author":"Wang","year":"2012","journal-title":"J Immunol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"2082","DOI":"10.1093\/cvr\/cvaf165","article-title":"CTLA-4-Ig therapy preserves cardiac function following myocardial infarction with reperfusion","volume":"121","author":"Noonan","year":"2025","journal-title":"Cardiovasc Res"},{"key":"B40","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1084\/jem.20081811","article-title":"CD4\u2009+\u2009regulatory T cells require CTLA-4 for the maintenance of systemic tolerance","volume":"206","author":"Friedline","year":"2009","journal-title":"J Exp Med"},{"key":"B41","doi-asserted-by":"publisher","first-page":"2707","DOI":"10.7150\/thno.68437","article-title":"CD4(+)FoxP3(+)CD73(+) Regulatory T cell promotes cardiac healing post-myocardial infarction","volume":"12","author":"Zhuang","year":"2022","journal-title":"Theranostics"},{"key":"B42","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1161\/CIRCRESAHA.106.147124","article-title":"CTLA-4 ablation and interleukin-12 driven differentiation synergistically augment cardiac pathogenicity of cytotoxic T lymphocytes","volume":"101","author":"Love","year":"2007","journal-title":"Circ Res"},{"key":"B43","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1172\/JCI96798","article-title":"Early B cell changes predict autoimmunity following combination immune checkpoint blockade","volume":"128","author":"Das","year":"2018","journal-title":"J Clin Invest"},{"key":"B44","doi-asserted-by":"publisher","first-page":"102300","DOI":"10.1016\/j.coi.2023.102300","article-title":"T-bet(high)CD21(low) B cells: the need to unify our understanding of a distinct B cell population in health and disease","volume":"82","author":"Keller","year":"2023","journal-title":"Curr Opin Immunol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"eabh0891","DOI":"10.1126\/sciimmunol.abh0891","article-title":"The expansion of human T-bet(high)CD21(low) B cells is T cell dependent","volume":"6","author":"Keller","year":"2021","journal-title":"Sci Immunol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"108364","DOI":"10.1016\/j.clim.2020.108364","article-title":"CD21(low) B cells in systemic sclerosis: a possible marker of vascular complications","volume":"213","author":"Marrapodi","year":"2020","journal-title":"Clin Immunol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.molimm.2024.05.002","article-title":"The roles of B cells in cardiovascular diseases","volume":"171","author":"Ma","year":"2024","journal-title":"Mol Immunol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"21673","DOI":"10.1073\/pnas.1911464116","article-title":"IL-10-producing B cells are enriched in murine pericardial adipose tissues and ameliorate the outcome of acute myocardial infarction","volume":"116","author":"Wu","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B49","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.jacc.2021.11.051","article-title":"Splenic marginal zone B lymphocytes regulate cardiac remodeling after acute myocardial infarction in mice","volume":"79","author":"Sun","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","article-title":"Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance","volume":"16","author":"Martins","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1007\/s00262-026-04298-y","article-title":"Complement contributes to ICI-triggered sialadenitis and predicts ICI efficacy","volume":"75","author":"Guan","year":"2026","journal-title":"Cancer Immunol Immunother"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2021-242075","article-title":"Presumed complement-mediated, checkpoint inhibitor-induced, thrombotic microangiopathy in a patient with metastatic melanoma","volume":"14","author":"Muniz","year":"2021","journal-title":"BMJ Case Rep"},{"key":"B53","doi-asserted-by":"publisher","first-page":"99","DOI":"10.3109\/08916939409009537","article-title":"Complement-mediated cytotoxic activity of anti-heart antibodies present in the sera of patients with dilated cardiomyopathy","volume":"19","author":"Latif","year":"1994","journal-title":"Autoimmunity"},{"key":"B54","doi-asserted-by":"publisher","first-page":"e0180424","DOI":"10.1128\/jvi.01804-24","article-title":"Mitochondrial injury and complement dysregulation are drivers of pathological inflammation in viral myocarditis","volume":"99","author":"Mohamud","year":"2025","journal-title":"J Virol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"101434","DOI":"10.1016\/j.bbrep.2023.101434","article-title":"The role of complement C3 in the outcome of regional myocardial infarction","volume":"33","author":"Fang","year":"2023","journal-title":"Biochem Biophys Rep"},{"key":"B56","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1172\/JCI116733","article-title":"The adipsin-acylation stimulating protein system and regulation of intracellular triglyceride synthesis","volume":"92","author":"Baldo","year":"1993","journal-title":"J Clin Invest"},{"key":"B57","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1002\/ehf2.14218","article-title":"Acylation-stimulating protein and heart failure progression in arrhythmogenic right ventricular cardiomyopathy","volume":"10","author":"Ren","year":"2023","journal-title":"ESC Heart Fail"},{"key":"B58","doi-asserted-by":"publisher","first-page":"e8732","DOI":"10.1590\/1414-431x20198732","article-title":"Ca2+\/calmodulin-dependent kinase II delta B is essential for cardiomyocyte hypertrophy and complement gene expression after LPS and HSP60 stimulation in vitro","volume":"52","author":"Cruz Junho","year":"2019","journal-title":"Braz J Med Biol Res"},{"key":"B59","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1172\/JCI35814","article-title":"Ca2+\/calmodulin-dependent kinase II triggers cell membrane injury by inducing complement factor B gene expression in the mouse heart","volume":"119","author":"Singh","year":"2009","journal-title":"J Clin Invest"},{"key":"B60","doi-asserted-by":"publisher","first-page":"102886","DOI":"10.1016\/j.arr.2025.102886","article-title":"Ca(2+)\/calmodulin-dependent protein kinase II (CaMKII)-targeted drug discovery: challenges and strategies","volume":"112","author":"Tian","year":"2025","journal-title":"Ageing Res Rev"},{"key":"B61","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1161\/CIRCRESAHA.109.194035","article-title":"CaMKII negatively regulates calcineurin-NFAT signaling in cardiac myocytes","volume":"105","author":"MacDonnell","year":"2009","journal-title":"Circ Res"},{"key":"B62","doi-asserted-by":"publisher","first-page":"4832","DOI":"10.4049\/jimmunol.181.7.4832","article-title":"NFATc1 regulates PD-1 expression upon T cell activation","volume":"181","author":"Oestreich","year":"2008","journal-title":"J Immunol"},{"key":"B63","doi-asserted-by":"publisher","first-page":"3831","DOI":"10.4049\/jimmunol.179.6.3831","article-title":"Induction of the CTLA-4 gene in human lymphocytes is dependent on NFAT binding the proximal promoter","volume":"179","author":"Gibson","year":"2007","journal-title":"J Immunol"},{"key":"B64","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1093\/ehjcvp\/pvag006","article-title":"Cardiac adverse events associated with dual immune checkpoint inhibitors: a pharmacovigilance analysis from the FDA adverse event reporting system","volume":"12","author":"Xia","year":"2026","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"B65","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","article-title":"Fulminant myocarditis with combination immune checkpoint blockade","volume":"375","author":"Johnson","year":"2016","journal-title":"N Engl J Med"},{"key":"B66","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1038\/s41586-022-05432-3","article-title":"T cells specific for alpha-myosin drive immunotherapy-related myocarditis","volume":"611","author":"Axelrod","year":"2022","journal-title":"Nature"},{"key":"B67","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/s41586-024-08105-5","article-title":"Immune responses in checkpoint myocarditis across heart, blood and tumour","volume":"636","author":"Blum","year":"2024","journal-title":"Nature"},{"key":"B68","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1038\/nri.2017.12","article-title":"Generation of diversity in thymic epithelial cells","volume":"17","author":"Takahama","year":"2017","journal-title":"Nat Rev Immunol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-026-04407-x","article-title":"Thymic epithelial tumors at the crossroads of immunity, autoimmunity, and immunotherapy","volume":"75","author":"Canaslan","year":"2026","journal-title":"Cancer Immunol Immunother"},{"key":"B70","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","article-title":"Myocarditis in patients treated with immune checkpoint inhibitors","volume":"71","author":"Mahmood","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"B71","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1038\/nri.2016.9","article-title":"AIRE Expands: new roles in immune tolerance and beyond","volume":"16","author":"Anderson","year":"2016","journal-title":"Nat Rev Immunol"},{"key":"B72","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1200\/JCO.2017.77.3184","article-title":"Pembrolizumab for patients with thymic epithelial tumor: immune-related adverse events and biomarkers","volume":"37","author":"Cho","year":"2019","journal-title":"J Clin Oncol"},{"key":"B73","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/S1470-2045(18)30062-7","article-title":"Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study","volume":"19","author":"Giaccone","year":"2018","journal-title":"Lancet Oncol"},{"key":"B74","first-page":"737","article-title":"Thymic epithelial neoplasia and the immune system: implications for autoimmunity","volume":"352","author":"Scadden","year":"2005","journal-title":"N Engl J Med"},{"key":"B75","doi-asserted-by":"publisher","first-page":"413","DOI":"10.3109\/08916930903555935","article-title":"Thymoma and paraneoplastic myasthenia gravis","volume":"43","author":"Marx","year":"2010","journal-title":"Autoimmunity"},{"key":"B76","doi-asserted-by":"publisher","first-page":"3100","DOI":"10.1038\/s41591-023-02591-2","article-title":"Thymus alterations and susceptibility to immune checkpoint inhibitor myocarditis","volume":"29","author":"Fenioux","year":"2023","journal-title":"Nat Med"},{"key":"B77","doi-asserted-by":"publisher","first-page":"1423622","DOI":"10.3389\/fimmu.2024.1423622","article-title":"Autoantibody profiling of patients with immune checkpoint inhibitor-associated myocarditis: a pilot study","volume":"15","author":"Li","year":"2024","journal-title":"Front Immunol"},{"key":"B78","doi-asserted-by":"publisher","first-page":"359","DOI":"10.21037\/atm.2019.04.86","article-title":"Paraneoplastic syndromes in lung cancer and their management","volume":"7","author":"Anwar","year":"2019","journal-title":"Ann Transl Med"},{"key":"B79","doi-asserted-by":"publisher","first-page":"251","DOI":"10.5114\/ada.2024.141114","article-title":"Paraneoplastic syndromes in patients with melanoma","volume":"41","author":"Dec","year":"2024","journal-title":"Postepy Dermatol Alergol"},{"key":"B80","doi-asserted-by":"publisher","first-page":"392.e311","DOI":"10.1016\/j.urolonc.2023.06.015","article-title":"Incidence and clinical relevance of paraneoplastic syndromes in patients with renal cell carcinoma","volume":"41","author":"Moldovan","year":"2023","journal-title":"Urol Oncol"},{"key":"B81","doi-asserted-by":"publisher","first-page":"102674","DOI":"10.1016\/j.jocmr.2025.102674","article-title":"The 2025 European society of cardiology guidelines for myocarditis and pericarditis and the evolving role of cardiovascular magnetic resonance","volume":"28","author":"Schulz-Menger","year":"2025","journal-title":"J Cardiovasc Magn Reson"},{"key":"B82","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1002\/ehf2.15281","article-title":"Immune checkpoint inhibitors and cardiovascular adverse events","volume":"12","author":"De Perna","year":"2025","journal-title":"ESC Heart Fail"},{"key":"B83","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1161\/CIRCRESAHA.124.324674","article-title":"Clinical characteristics and mechanisms of acute myocarditis","volume":"135","author":"Heymans","year":"2024","journal-title":"Circ Res"},{"key":"B84","doi-asserted-by":"publisher","first-page":"e041163","DOI":"10.1161\/JAHA.125.041163","article-title":"Short- and long-term outcomes of pericarditis, myocarditis, and myopericarditis in patients with malignancy on immune checkpoint inhibitors","volume":"15","author":"Agrawal","year":"2026","journal-title":"J Am Heart Assoc"},{"key":"B85","doi-asserted-by":"publisher","first-page":"1550400","DOI":"10.3389\/fimmu.2025.1550400","article-title":"ICI-induced cardiovascular toxicity: mechanisms and immune reprogramming therapeutic strategies","volume":"16","author":"Zheng","year":"2025","journal-title":"Front Immunol"},{"key":"B86","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1161\/CIRCULATIONAHA.119.043171","article-title":"Heart-Specific immune responses in an animal model of autoimmune-related myocarditis mitigated by an immunoproteasome inhibitor and genetic ablation","volume":"141","author":"Bockstahler","year":"2020","journal-title":"Circulation"},{"key":"B87","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1172\/JCI44583","article-title":"Impaired thymic tolerance to alpha-myosin directs autoimmunity to the heart in mice and humans","volume":"121","author":"Lv","year":"2011","journal-title":"J Clin Invest"},{"key":"B88","doi-asserted-by":"publisher","first-page":"1677984","DOI":"10.3389\/fimmu.2025.1677984","article-title":"Overview of immune checkpoint inhibitor associated myocarditis mechanisms diagnostics and treatment","volume":"16","author":"Feng","year":"2025","journal-title":"Front Immunol"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1172\/JCI145186","article-title":"Immune checkpoint inhibitor-associated myocarditis: manifestations and mechanisms","volume":"131","author":"Moslehi","year":"2021","journal-title":"J Clin Invest"},{"key":"B90","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/s41392-025-02326-4","article-title":"Regulatory T cells in homeostasis and disease: molecular mechanisms and therapeutic potential","volume":"10","author":"Wang","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"B91","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1159\/000067596","article-title":"The role of IL-10 and TGF-beta in the differentiation and effector function of T regulatory cells","volume":"129","author":"Levings","year":"2002","journal-title":"Int Arch Allergy Immunol"},{"key":"B92","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1038\/s41423-023-01036-7","article-title":"Intricacies of TGF-beta signaling in treg and Th17 cell biology","volume":"20","author":"Wang","year":"2023","journal-title":"Cell Mol Immunol"},{"key":"B93","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"key":"B94","doi-asserted-by":"publisher","first-page":"4735","DOI":"10.1158\/1078-0432.CCR-18-4083","article-title":"Myocarditis in cynomolgus monkeys following treatment with immune checkpoint inhibitors","volume":"25","author":"Ji","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.116.003514","article-title":"Acute lymphocytic myocarditis with anti-PD-1 antibody nivolumab","volume":"9","author":"Tadokoro","year":"2016","journal-title":"Circ Heart Fail"},{"key":"B96","doi-asserted-by":"publisher","first-page":"111611","DOI":"10.1016\/j.celrep.2022.111611","article-title":"Cardiac myosin-specific autoimmune T cells contribute to immune-checkpoint-inhibitor-associated myocarditis","volume":"41","author":"Won","year":"2022","journal-title":"Cell Rep"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20251717","article-title":"Immune checkpoint inhibitor-induced myocarditis is dependent on CD8T cell-derived TNF and TNFR2 signaling","volume":"223","author":"Warrick","year":"2026","journal-title":"J Exp Med"},{"key":"B98","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1161\/CIRCULATIONAHA.121.056730","article-title":"Identification of pathogenic immune cell subsets associated with checkpoint inhibitor-induced myocarditis","volume":"146","author":"Zhu","year":"2022","journal-title":"Circulation"},{"key":"B99","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1038\/s44161-025-00633-1","article-title":"The immune checkpoint regulator CD40 potentiates myocardial inflammation","volume":"4","author":"Jimenez","year":"2025","journal-title":"Nat Cardiovasc Res"},{"key":"B100","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1161\/CIRCULATIONAHA.122.062551","article-title":"Expansion of pathogenic cardiac macrophages in immune checkpoint inhibitor myocarditis","volume":"149","author":"Ma","year":"2024","journal-title":"Circulation"},{"key":"B101","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1186\/s12943-024-02156-y","article-title":"Regulatory T cells in immune checkpoint blockade antitumor therapy","volume":"23","author":"Zhang","year":"2024","journal-title":"Mol Cancer"},{"key":"B102","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/S0008-6363(03)00334-1","article-title":"Attenuation of experimental autoimmune myocarditis by blocking activated T cells through inducible costimulatory molecule pathway","volume":"59","author":"Futamatsu","year":"2003","journal-title":"Cardiovasc Res"},{"key":"B103","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1093\/jleuko\/qiad143","article-title":"Role of immune cells in the pathogenesis of myocarditis","volume":"115","author":"Liu","year":"2024","journal-title":"J Leukoc Biol"},{"key":"B104","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1158\/2326-6066.CIR-24-0011","article-title":"Molecular pathways and cellular subsets associated with adverse clinical outcomes in overlapping immune-related myocarditis and myositis","volume":"12","author":"Siddiqui","year":"2024","journal-title":"Cancer Immunol Res"},{"key":"B105","article-title":"Immune responses in checkpoint myocarditis across heart, blood, and tumor","author":"Blum","year":"2023","journal-title":"bioRxiv"},{"key":"B106","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/90686","article-title":"Contribution of the innate immune system to autoimmune myocarditis: a role for complement","volume":"2","author":"Kaya","year":"2001","journal-title":"Nat Immunol"},{"key":"B107","doi-asserted-by":"publisher","first-page":"12032","DOI":"10.1200\/JCO.2024.42.16_suppl.12032","article-title":"Effect of anti CTLA-4 and PD-1 monoclonal antibodies on systemic SDF-1 and galectin-3 levels through NLRP3 and MyD-88 pathways in preclinical models","volume":"42","author":"Iovine","year":"2024","journal-title":"J Clin Oncol"},{"key":"B108","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/2193-1801-1-63","article-title":"Complement anaphylatoxins C3a and C5a induce a failing regenerative program in cardiac resident cells. Evidence of a role for cardiac resident stem cells other than cardiomyocyte renewal","volume":"1","author":"Lara-Astiaso","year":"2012","journal-title":"Springerplus"},{"key":"B109","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1001\/jamacardio.2021.2241","article-title":"Clinical strategy for the diagnosis and treatment of immune checkpoint inhibitor-associated myocarditis: a narrative review","volume":"6","author":"Lehmann","year":"2021","journal-title":"JAMA Cardiol"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001887","article-title":"Intensified immunosuppressive therapy in patients with immune checkpoint inhibitor-induced myocarditis","volume":"8","author":"Cautela","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B111","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1056\/NEJMc1903064","article-title":"Alemtuzumab for immune-related myocarditis due to PD-1 therapy","volume":"380","author":"Esfahani","year":"2019","journal-title":"N Engl J Med"},{"key":"B112","doi-asserted-by":"publisher","first-page":"2624","DOI":"10.1016\/j.jacc.2025.11.016","article-title":"2026 ACC\/AHA\/AACVPR\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of dyslipidemia: a report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines","volume":"87","author":"Blumenthal","year":"2026","journal-title":"J Am Coll Cardiol"},{"key":"B113","doi-asserted-by":"publisher","first-page":"2299","DOI":"10.1161\/CIRCULATIONAHA.120.049981","article-title":"Association between immune checkpoint inhibitors with cardiovascular events and atherosclerotic plaque","volume":"142","author":"Drobni","year":"2020","journal-title":"Circulation"},{"key":"B114","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.ejca.2019.06.021","article-title":"Acute vascular events as a possibly related adverse event of immunotherapy: a single-institute retrospective study","volume":"120","author":"Bar","year":"2019","journal-title":"Eur J Cancer"},{"key":"B115","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23063346","article-title":"Pathophysiology of atherosclerosis","volume":"23","author":"Jebari-Benslaiman","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B116","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s00395-024-01046-0","article-title":"Early microvascular coronary endothelial dysfunction precedes pembrolizumab-induced cardiotoxicity. Preventive role of high dose of atorvastatin","volume":"120","author":"Efentakis","year":"2025","journal-title":"Basic Res Cardiol"},{"key":"B117","doi-asserted-by":"publisher","first-page":"1604989","DOI":"10.3389\/fimmu.2025.1604989","article-title":"The impact of immune checkpoint inhibition on atherosclerosis in cancer patients","volume":"16","author":"Han","year":"2025","journal-title":"Front Immunol"},{"key":"B118","doi-asserted-by":"publisher","first-page":"25065","DOI":"10.1038\/s41598-025-06937-3","article-title":"Construction of a macrophage-related prognostic signature and assessment of immune checkpoint inhibitor efficacy of HCC","volume":"15","author":"Zang","year":"2025","journal-title":"Sci Rep"},{"key":"B119","doi-asserted-by":"publisher","first-page":"e322","DOI":"10.1161\/ATVBAHA.119.314238","article-title":"Epac1 (exchange protein directly activated by cAMP 1) upregulates LOX-1 (oxidized low-density lipoprotein receptor 1) to promote foam cell formation and atherosclerosis development","volume":"40","author":"Robichaux","year":"2020","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"B120","doi-asserted-by":"publisher","first-page":"e70350","DOI":"10.1111\/ppl.70350","article-title":"Unraveling the role of TARGET OF RAPAMYCIN in the immune response of Cucumis sativus to Podosphaera xanthii","volume":"177","author":"Yu","year":"2025","journal-title":"Physiol Plant"},{"key":"B121","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1194\/jlr.D000497","article-title":"The role of CD4\u2009+\u2009CD25\u2009+\u2009regulatory T cells in macrophage-derived foam-cell formation","volume":"51","author":"Lin","year":"2010","journal-title":"J Lipid Res"},{"key":"B122","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1007\/s11936-023-01024-0","article-title":"Immunotherapy-Associated atherosclerosis: a comprehensive review of recent findings and implications for future research","volume":"25","author":"Chan","year":"2023","journal-title":"Curr Treat Options Cardiovasc Med"},{"key":"B123","doi-asserted-by":"publisher","first-page":"15818","DOI":"10.1073\/pnas.2006348117","article-title":"Clonally expanding smooth muscle cells promote atherosclerosis by escaping efferocytosis and activating the complement cascade","volume":"117","author":"Wang","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B124","doi-asserted-by":"publisher","first-page":"S9","DOI":"10.1186\/ar2193","article-title":"Vasculitis: mechanisms involved and clinical manifestations","volume":"9","author":"Guillevin","year":"2007","journal-title":"Arthritis Res Ther"},{"key":"B125","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s41927-025-00528-5","article-title":"Immune checkpoint inhibitor associated vasculitis and polymyalgia rheumatica: a case series and systematic review","volume":"9","author":"Teel","year":"2025","journal-title":"BMC Rheumatol"},{"key":"B126","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s12882-023-03091-8","article-title":"Immune checkpoint inhibitors associated granulomatous small vessel vasculitis accompanied with tubulointerstitial nephritis: a case report","volume":"24","author":"Tominaga","year":"2023","journal-title":"BMC Nephrol"},{"key":"B127","doi-asserted-by":"publisher","first-page":"986357","DOI":"10.3389\/fphar.2022.986357","article-title":"Cardiac arrhythmias associated with immune checkpoint inhibitors: a comprehensive disproportionality analysis of the FDA adverse event reporting system","volume":"13","author":"Wang","year":"2022","journal-title":"Front Pharmacol"},{"key":"B128","doi-asserted-by":"publisher","first-page":"6637","DOI":"10.1002\/cam4.5438","article-title":"Arrhythmic events associated with immune checkpoint inhibitors therapy: a real-world study based on the food and drug administration adverse event reporting system database","volume":"12","author":"Liu","year":"2023","journal-title":"Cancer Med"},{"key":"B129","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1161\/CIRCULATIONAHA.121.055816","article-title":"Electrocardiographic manifestations of immune checkpoint inhibitor myocarditis","volume":"144","author":"Power","year":"2021","journal-title":"Circulation"},{"key":"B130","doi-asserted-by":"publisher","first-page":"930797","DOI":"10.3389\/fcvm.2022.930797","article-title":"Immune checkpoint inhibitor therapy increases systemic SDF-1, cardiac DAMPs fibronectin-EDA, S100\/calgranulin, galectine-3, and NLRP3-MyD88-chemokine pathways","volume":"9","author":"Quagliariello","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"B131","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1002\/j.2040-4603.2017.tb00771.x","article-title":"Cardiac fibrosis and arrhythmogenesis","volume":"7","author":"Nguyen","year":"2017","journal-title":"Compr Physiol"},{"key":"B132","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.yjmcc.2013.10.018","article-title":"Cardiac fibrosis and arrhythmogenesis: the road to repair is paved with perils","volume":"70","author":"Nguyen","year":"2014","journal-title":"J Mol Cell Cardiol"},{"key":"B133","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.2169\/internalmedicine.8575-21","article-title":"Sinus node dysfunction co-occurring with immune checkpoint inhibitor-associated myocarditis","volume":"61","author":"Nishikawa","year":"2022","journal-title":"Intern Med"},{"key":"B134","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.cjco.2023.08.013","article-title":"Immune checkpoint inhibitor-associated myocarditis: a rare presentation with atrioventricular block and Sinus node dysfunction","volume":"5","author":"Cardoso","year":"2023","journal-title":"CJC Open"},{"key":"B135","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1200\/JCO.18.02464","article-title":"Identification and management of immune checkpoint inhibitor-related myocarditis: use troponin wisely","volume":"37","author":"Spallarossa","year":"2019","journal-title":"J Clin Oncol"},{"key":"B136","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1007\/s00262-021-02855-1","article-title":"Cytokine changes during immune-related adverse events and corticosteroid treatment in melanoma patients receiving immune checkpoint inhibitors","volume":"70","author":"Tyan","year":"2021","journal-title":"Cancer Immunol Immunother"},{"key":"B137","doi-asserted-by":"publisher","first-page":"e008627","DOI":"10.1161\/CIRCEP.120.008627","article-title":"Cardiac arrest risk during acute infections: systemic inflammation directly prolongs QTc interval via cytokine-mediated effects on potassium channel expression","volume":"13","author":"Lazzerini","year":"2020","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"B138","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41577-022-00714-3","article-title":"Inflammatory cytokines and cardiac arrhythmias: the lesson from COVID-19","volume":"22","author":"Lazzerini","year":"2022","journal-title":"Nat Rev Immunol"},{"key":"B139","doi-asserted-by":"publisher","first-page":"1784935","DOI":"10.3389\/fimmu.2026.1784935","article-title":"Spatiotemporal control of immunogenic cell death: rewiring tumor-immune dialogues for next-generation immunotherapy","volume":"17","author":"Li","year":"2026","journal-title":"Front Immunol"},{"key":"B140","doi-asserted-by":"publisher","first-page":"621","DOI":"10.2217\/imt-2020-0224","article-title":"Immune checkpoint inhibitors and chemotherapy in first-line NSCLC: a meta-analysis","volume":"13","author":"Petrelli","year":"2021","journal-title":"Immunotherapy"},{"key":"B141","first-page":"477","article-title":"Cabozantinib plus nivolumab and ipilimumab in renal-cell carcinoma. Reply","volume":"389","author":"Choueiri","year":"2023","journal-title":"N Engl J Med"},{"key":"B142","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1200\/JCO.21.01485","article-title":"Neoadjuvant atezolizumab with gemcitabine and cisplatin in patients with muscle-invasive bladder cancer: a multicenter, single-arm, phase II trial","volume":"40","author":"Funt","year":"2022","journal-title":"J Clin Oncol"},{"key":"B143","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.annonc.2024.02.002","article-title":"Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522","volume":"35","author":"Pusztai","year":"2024","journal-title":"Ann Oncol"},{"key":"B144","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/S0140-6736(21)01234-4","article-title":"Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study","volume":"398","author":"Sun","year":"2021","journal-title":"Lancet"},{"key":"B145","doi-asserted-by":"publisher","first-page":"263","DOI":"10.2165\/00002018-200022040-00002","article-title":"Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention","volume":"22","author":"Pai","year":"2000","journal-title":"Drug Saf"},{"key":"B146","doi-asserted-by":"publisher","first-page":"e410","DOI":"10.1093\/oncolo\/oyac056","article-title":"Incidence, clinical characteristics, and predictors of cardiovascular immune-related adverse events associated with immune checkpoint inhibitors","volume":"27","author":"Isawa","year":"2022","journal-title":"Oncologist"},{"key":"B147","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.lungcan.2020.10.017","article-title":"Cardiovascular toxicity in patients treated with immunotherapy for metastatic non-small cell lung cancer: a SEER-medicare study: cVD outcomes with the use of ICI in mNSCLC","volume":"150","author":"Bishnoi","year":"2020","journal-title":"Lung Cancer"},{"key":"B148","doi-asserted-by":"publisher","first-page":"645245","DOI":"10.3389\/fonc.2021.645245","article-title":"Risk of cardiac adverse events in patients treated with immune checkpoint inhibitor regimens: a systematic review and meta-analysis","volume":"11","author":"Hu","year":"2021","journal-title":"Front Oncol"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14092320","article-title":"Cancer therapy-related cardiac dysfunction in patients treated with a combination of an immune checkpoint inhibitor and doxorubicin","volume":"14","author":"Lee","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B150","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1158\/1078-0432.CCR-22-1366","article-title":"Molecular mechanisms and future implications of VEGF\/VEGFR in cancer therapy","volume":"29","author":"Patel","year":"2023","journal-title":"Clin Cancer Res"},{"key":"B151","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1084\/jem.20140559","article-title":"VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors","volume":"212","author":"Voron","year":"2015","journal-title":"J Exp Med"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aak9679","article-title":"Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation","volume":"9","author":"Allen","year":"2017","journal-title":"Sci Transl Med"},{"key":"B153","doi-asserted-by":"publisher","first-page":"e71769","DOI":"10.1002\/cam4.71769","article-title":"Tumor anti-angiogenesis therapy and its influence on immune cell function in the tumor microenvironment","volume":"15","author":"Tang","year":"2026","journal-title":"Cancer Med"},{"key":"B154","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1002\/JLB.5RU0222-082R","article-title":"Direct and indirect regulation of the tumor immune microenvironment by VEGF","volume":"111","author":"Zhang","year":"2022","journal-title":"J Leukoc Biol"},{"key":"B155","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1038\/nm1096-1096","article-title":"Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells","volume":"2","author":"Gabrilovich","year":"1996","journal-title":"Nat Med"},{"key":"B156","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1158\/0008-5472.CAN-12-2325","article-title":"VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer","volume":"73","author":"Terme","year":"2013","journal-title":"Cancer Res"},{"key":"B157","doi-asserted-by":"publisher","first-page":"102295","DOI":"10.1016\/j.ctrv.2021.102295","article-title":"Efficacy of VEGFR-TKIs plus immune checkpoint inhibitors in metastatic renal cell carcinoma patients with favorable IMDC prognosis","volume":"100","author":"Ciccarese","year":"2021","journal-title":"Cancer Treat Rev"},{"key":"B158","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"key":"B159","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1007\/s40261-018-0709-2","article-title":"Cardiovascular toxicities with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a meta-analysis of 77 randomized controlled trials","volume":"38","author":"Li","year":"2018","journal-title":"Clin Drug Investig"},{"key":"B160","doi-asserted-by":"publisher","first-page":"104059","DOI":"10.1016\/j.critrevonc.2023.104059","article-title":"Comparing cardiovascular adverse events in cancer patients: a meta-analysis of combination therapy with angiogenesis inhibitors and immune checkpoint inhibitors versus angiogenesis inhibitors alone","volume":"188","author":"Crocetto","year":"2023","journal-title":"Crit Rev Oncol Hematol"},{"key":"B161","doi-asserted-by":"publisher","first-page":"e101286","DOI":"10.1371\/journal.pone.0101286","article-title":"Clinical profiling of BCL-2 family members in the setting of BRAF inhibition offers a rationale for targeting de novo resistance using BH3 mimetics","volume":"9","author":"Frederick","year":"2014","journal-title":"PLoS One"},{"key":"B162","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1158\/1078-0432.CCR-12-1630","article-title":"BRAF Inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma","volume":"19","author":"Frederick","year":"2013","journal-title":"Clin Cancer Res"},{"key":"B163","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1001\/jamaoncol.2020.4401","article-title":"Rationale for immune checkpoint inhibitors plus targeted therapy in metastatic melanoma: a review","volume":"6","author":"Dummer","year":"2020","journal-title":"JAMA Oncol"},{"key":"B164","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/j.jaccao.2023.04.004","article-title":"Cardiotoxicity of BRAF\/MEK inhibitors: a longitudinal study incorporating contemporary definitions and risk scores","volume":"5","author":"Glen","year":"2023","journal-title":"JACC CardioOncol"},{"key":"B165","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1016\/S0140-6736(20)30934-X","article-title":"Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAF(V600) mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial","volume":"395","author":"Gutzmer","year":"2020","journal-title":"Lancet"},{"key":"B166","doi-asserted-by":"publisher","first-page":"1680838","DOI":"10.3389\/fimmu.2025.1680838","article-title":"Combination of PD-1\/PD-L1 and CTLA-4 inhibitors in the treatment of cancer - a brief update","volume":"16","author":"Park","year":"2025","journal-title":"Front Immunol"},{"key":"B167","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1001\/jamaoncol.2025.4543","article-title":"Immune checkpoint inhibitor-associated cardiovascular toxic effects: international cardio-oncology society position statement","volume":"12","author":"Herrmann","year":"2026","journal-title":"JAMA Oncol"},{"key":"B168","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1002\/ejhf.2289","article-title":"Cardiotoxicity associated with immune checkpoint inhibitor therapy: a meta-analysis","volume":"23","author":"Rubio-Infante","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"B169","doi-asserted-by":"publisher","first-page":"e013757","DOI":"10.1161\/JAHA.119.013757","article-title":"Immune checkpoint inhibitor myocarditis: pathophysiological characteristics, diagnosis, and treatment","volume":"9","author":"Palaskas","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"B170","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1007\/s11912-023-01414-4","article-title":"Risk factors for immune checkpoint inhibitor-mediated cardiovascular toxicities","volume":"25","author":"Yousif","year":"2023","journal-title":"Curr Oncol Rep"},{"key":"B171","doi-asserted-by":"publisher","first-page":"3158","DOI":"10.1016\/j.jacc.2018.09.072","article-title":"Cardiovascular magnetic resonance in nonischemic myocardial inflammation: expert recommendations","volume":"72","author":"Ferreira","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"B172","doi-asserted-by":"publisher","first-page":"101478","DOI":"10.1016\/j.cpcardiol.2022.101478","article-title":"Electrocardiographic features of immune checkpoint inhibitor-associated myocarditis","volume":"48","author":"Song","year":"2023","journal-title":"Curr Probl Cardiol"},{"key":"B173","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-002007","article-title":"Electrocardiographic features of immune checkpoint inhibitor associated myocarditis","volume":"9","author":"Zlotoff","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B174","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1093\/eurheartj\/ehn189","article-title":"The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology","volume":"29","author":"Anderson","year":"2008","journal-title":"Eur Heart J"},{"key":"B175","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1016\/j.jacc.2007.09.008","article-title":"The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology. Endorsed by the heart failure society of America and the heart failure association of the European Society of Cardiology","volume":"50","author":"Cooper","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"B176","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.jaccao.2025.06.009","article-title":"Cardiac troponin screening and clinical outcomes in patients receiving immunotherapy","volume":"7","author":"Cheng","year":"2025","journal-title":"JACC CardioOncol"},{"key":"B177","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC guidelines on cardio-oncology developed in collaboration with the European hematology association (EHA), the European society for therapeutic radiology and oncology (ESTRO) and the international cardio-oncology society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur Heart J"},{"key":"B178","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1016\/j.jaccao.2024.07.001","article-title":"Cardiac troponin I and T in ICI myocarditis screening, diagnosis, and prognosis","volume":"6","author":"Barac","year":"2024","journal-title":"JACC CardioOncol"},{"key":"B179","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.jaccao.2025.09.008","article-title":"Proactive surveillance for ICI cardiotoxicity: progress and next frontiers","volume":"8","author":"Dziewierz","year":"2026","journal-title":"JACC CardioOncol"},{"key":"B180","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.jaccao.2021.01.004","article-title":"Myocarditis surveillance with high-sensitivity troponin I during cancer treatment with immune checkpoint inhibitors","volume":"3","author":"Waliany","year":"2021","journal-title":"JACC CardioOncol"},{"key":"B181","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.jjcc.2022.07.009","article-title":"Prospective screening for myocarditis in cancer patients treated with immune checkpoint inhibitors","volume":"81","author":"Furukawa","year":"2023","journal-title":"J Cardiol"},{"key":"B182","doi-asserted-by":"publisher","first-page":"101374","DOI":"10.1016\/j.jacadv.2024.101374","article-title":"Evaluating troponin-based monitoring in patients undergoing immune checkpoint inhibitor therapy","volume":"3","author":"Tamura","year":"2024","journal-title":"JACC Adv"},{"key":"B183","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1515\/CCLM.1999.158","article-title":"The specificity of biochemical markers of cardiac damage: a problem solved","volume":"37","author":"Apple","year":"1999","journal-title":"Clin Chem Lab Med"},{"key":"B184","doi-asserted-by":"publisher","first-page":"e20020","DOI":"10.7717\/peerj.20020","article-title":"NT-proBNP serves as a prognostic marker for adverse outcomes in severe immune checkpoint inhibitor-associated myocarditis","volume":"13","author":"He","year":"2025","journal-title":"PeerJ"},{"key":"B185","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1042\/CS20200331","article-title":"Mechanisms and clinical manifestations of cardiovascular toxicities associated with immune checkpoint inhibitors","volume":"135","author":"Baik","year":"2021","journal-title":"Clin Sci (Lond)"},{"key":"B186","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1002\/clc.24149","article-title":"Plasma exchange plus glucocorticoids in the treatment of immune checkpoint inhibitor-induced myocarditis: a case series and review","volume":"46","author":"Ke","year":"2023","journal-title":"Clin Cardiol"},{"key":"B187","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1093\/cvr\/cvad029","article-title":"Inhibition of phosphoglycerate kinase 1 attenuates autoimmune myocarditis by reprogramming CD4+ T cell metabolism","volume":"119","author":"Lu","year":"2023","journal-title":"Cardiovasc Res"},{"key":"B188","doi-asserted-by":"publisher","first-page":"e0217761","DOI":"10.1371\/journal.pone.0217761","article-title":"Differential effects of 2-deoxy-D-glucose on in vitro expanded human regulatory T cell subsets","volume":"14","author":"Tanimine","year":"2019","journal-title":"PLoS One"},{"key":"B189","doi-asserted-by":"publisher","first-page":"581641","DOI":"10.3389\/fcell.2020.581641","article-title":"Inhibition of PFKFB3 hampers the progression of atherosclerosis and promotes plaque stability","volume":"8","author":"Poels","year":"2020","journal-title":"Front Cell Dev Biol"},{"key":"B190","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1038\/ni.2556","article-title":"Control of amino-acid transport by antigen receptors coordinates the metabolic reprogramming essential for T cell differentiation","volume":"14","author":"Sinclair","year":"2013","journal-title":"Nat Immunol"},{"key":"B191","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s00262-023-03590-5","article-title":"Protective effect of low-intensity pulsed ultrasound on immune checkpoint inhibitor-related myocarditis via fine-tuning CD4(+) T-cell differentiation","volume":"73","author":"Fu","year":"2024","journal-title":"Cancer Immunol Immunother"},{"key":"B192","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1016\/j.annonc.2020.05.005","article-title":"Tocilizumab for refractory severe immune checkpoint inhibitor-associated myocarditis","volume":"31","author":"Doms","year":"2020","journal-title":"Ann Oncol"},{"key":"B193","doi-asserted-by":"publisher","first-page":"669","DOI":"10.3389\/fphys.2020.00669","article-title":"Notch3 modulates cardiac fibroblast proliferation, apoptosis, and fibroblast to myofibroblast transition via negative regulation of the RhoA\/ROCK\/Hif1alpha axis","volume":"11","author":"Shi","year":"2020","journal-title":"Front Physiol"},{"key":"B194","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222312916","article-title":"Rho-Kinase as a target for cancer therapy and its immunotherapeutic potential","volume":"22","author":"Kim","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B195","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1016\/j.cell.2015.08.016","article-title":"Metabolic competition in the tumor microenvironment is a driver of cancer progression","volume":"162","author":"Chang","year":"2015","journal-title":"Cell"},{"key":"B196","doi-asserted-by":"publisher","first-page":"200","DOI":"10.15252\/emmm.201708089","article-title":"The immunoproteasome-specific inhibitor ONX 0914 reverses susceptibility to acute viral myocarditis","volume":"10","author":"Althof","year":"2018","journal-title":"EMBO Mol Med"},{"key":"B197","doi-asserted-by":"publisher","first-page":"4182","DOI":"10.4049\/jimmunol.1201183","article-title":"Immunoproteasome subunit LMP7 deficiency and inhibition suppresses Th1 and Th17 but enhances regulatory T cell differentiation","volume":"189","author":"Kalim","year":"2012","journal-title":"J Immunol"},{"key":"B198","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s00395-021-00848-w","article-title":"Mitigated viral myocarditis in A\/J mice by the immunoproteasome inhibitor ONX 0914 depends on inhibition of systemic inflammatory responses in CoxsackievirusB3 infection","volume":"116","author":"Goetzke","year":"2021","journal-title":"Basic Res Cardiol"},{"key":"B199","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1093\/cvr\/cvr148","article-title":"IL-6-mediated Th17 differentiation through RORgammat is essential for the initiation of experimental autoimmune myocarditis","volume":"91","author":"Yamashita","year":"2011","journal-title":"Cardiovasc Res"},{"key":"B200","doi-asserted-by":"publisher","first-page":"660490","DOI":"10.3389\/fphar.2021.660490","article-title":"The hyperlipidaemic drug fenofibrate significantly reduces infection by SARS-CoV-2 in cell culture models","volume":"12","author":"Davies","year":"2021","journal-title":"Front Pharmacol"},{"key":"B201","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.7150\/jca.24488","article-title":"Anticancer properties of fenofibrate: a repurposing use","volume":"9","author":"Lian","year":"2018","journal-title":"J Cancer"},{"key":"B202","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/s41420-020-00349-0","article-title":"The caspase-3\/GSDME signal pathway as a switch between apoptosis and pyroptosis in cancer","volume":"6","author":"Jiang","year":"2020","journal-title":"Cell Death Discov"},{"key":"B203","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1038\/s41577-021-00524-z","article-title":"The cGAS-STING pathway as a therapeutic target in inflammatory diseases","volume":"21","author":"Decout","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"B204","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1161\/CIRCRESAHA.124.325652","article-title":"Novel therapeutic approach targeting CXCR3 to treat immunotherapy myocarditis","volume":"136","author":"Huang","year":"2025","journal-title":"Circ Res"},{"key":"B205","doi-asserted-by":"publisher","first-page":"16029","DOI":"10.1073\/pnas.1406508111","article-title":"Distinct macrophage lineages contribute to disparate patterns of cardiac recovery and remodeling in the neonatal and adult heart","volume":"111","author":"Lavine","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B206","author":"Hannah","year":"2024"},{"key":"B207","author":"Otto","year":"2024"},{"key":"B208","author":"Jiajun","year":"2024"},{"key":"B209","author":"M\u00fcller-Jensen","year":"2025"},{"key":"B210","author":"Xiaoting","year":"2025"},{"key":"B211","author":"Lalevee","year":"2025"},{"key":"B212","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.5858\/arpa.2019-0447-OA","article-title":"Histopathologic characterization of myocarditis associated with immune checkpoint inhibitor therapy","volume":"144","author":"Sobol","year":"2020","journal-title":"Arch Pathol Lab Med"},{"key":"B213","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/s41379-019-0363-0","article-title":"Immune checkpoint inhibitor associated myocarditis occurs in both high-grade and low-grade forms","volume":"33","author":"Champion","year":"2020","journal-title":"Mod Pathol"},{"key":"B214","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13205218","article-title":"Cardiac toxicity associated with immune checkpoint inhibitors: a systematic review","volume":"13","author":"Shalata","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B215","doi-asserted-by":"publisher","DOI":"10.3390\/diseases12050088","article-title":"Elevated IL-6 and tumor necrosis factor-alpha in immune checkpoint inhibitor myocarditis","volume":"12","author":"Ali","year":"2024","journal-title":"Diseases"},{"key":"B216","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1007\/s11033-025-11095-w","article-title":"Cytokine profiling of patients with immune checkpoint inhibitor-associated myocarditis: a pilot study","volume":"52","author":"Li","year":"2025","journal-title":"Mol Biol Rep"},{"key":"B217","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1007\/s12012-024-09918-6","article-title":"Steroid-Refractory myocarditis induced by immune checkpoint inhibitor responded to infliximab: report of two cases and literature review","volume":"24","author":"Tan","year":"2024","journal-title":"Cardiovasc Toxicol"},{"key":"B218","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1093\/intimm\/dxq026","article-title":"PD-1 deficiency results in the development of fatal myocarditis in MRL mice","volume":"22","author":"Wang","year":"2010","journal-title":"Int Immunol"},{"key":"B219","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1111\/bph.15984","article-title":"Characterization of immune checkpoint inhibitor-induced cardiotoxicity reveals interleukin-17A as a driver of cardiac dysfunction after anti-PD-1 treatment","volume":"180","author":"Gergely","year":"2023","journal-title":"Br J Pharmacol"},{"key":"B220","doi-asserted-by":"publisher","first-page":"20547","DOI":"10.1038\/s41598-025-05635-4","article-title":"Abnormal gut microbiota may cause PD-1 inhibitor-related cardiotoxicity via suppressing regulatory T cells","volume":"15","author":"Cao","year":"2025","journal-title":"Sci Rep"},{"key":"B221","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1158\/2326-6066.CIR-20-0969","article-title":"Regulatory T-cell transcriptomic reprogramming characterizes adverse events by checkpoint inhibitors in solid tumors","volume":"9","author":"Grigoriou","year":"2021","journal-title":"Cancer Immunol Res"},{"key":"B222","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1056\/NEJMc1901677","article-title":"Abatacept For severe immune checkpoint inhibitor-associated myocarditis","volume":"380","author":"Salem","year":"2019","journal-title":"N Engl J Med"},{"key":"B223","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1158\/2159-8290.CD-20-0856","article-title":"A genetic mouse model recapitulates immune checkpoint inhibitor-associated myocarditis and supports a mechanism-based therapeutic intervention","volume":"11","author":"Wei","year":"2021","journal-title":"Cancer Discov"},{"key":"B224","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1126\/science.1255904","article-title":"Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4","volume":"345","author":"Kuehn","year":"2014","journal-title":"Science"},{"key":"B225","doi-asserted-by":"publisher","first-page":"343","DOI":"10.4049\/jimmunol.152.1.343","article-title":"Induction of multiple heart autoantibodies in mice with coxsackievirus B3- and cardiac myosin-induced autoimmune myocarditis","volume":"152","author":"Neumann","year":"1994","journal-title":"J Immunol"},{"key":"B226","doi-asserted-by":"publisher","first-page":"2180951","DOI":"10.1080\/21505594.2023.2180951","article-title":"Immune mechanisms of group B coxsackievirus induced viral myocarditis","volume":"14","author":"Zhang","year":"2023","journal-title":"Virulence"},{"key":"B227","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1016\/j.immuni.2014.12.005","article-title":"The coinhibitory receptor CTLA-4 controls B cell responses by modulating T follicular helper, T follicular regulatory, and T regulatory cells","volume":"41","author":"Sage","year":"2014","journal-title":"Immunity"},{"key":"B228","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200177","article-title":"Immune checkpoint inhibition-related myasthenia-myositis-myocarditis responsive to complement blockade","volume":"11","author":"Nelke","year":"2024","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B229","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1161\/CIRCULATIONAHA.119.044703","article-title":"Major adverse cardiovascular events and the timing and dose of corticosteroids in immune checkpoint inhibitor-associated myocarditis","volume":"141","author":"Zhang","year":"2020","journal-title":"Circulation"},{"key":"B230","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.cjco.2020.11.004","article-title":"Plasma exchange for immune checkpoint inhibitor-induced myocarditis","volume":"3","author":"Yogasundaram","year":"2021","journal-title":"CJC Open"},{"key":"B231","doi-asserted-by":"publisher","first-page":"ytab342","DOI":"10.1093\/ehjcr\/ytab342","article-title":"A case report of immune checkpoint inhibitor-related steroid-refractory myocarditis and myasthenia gravis-like myositis treated with Abatacept and mycophenolate mofetil","volume":"5","author":"Jespersen","year":"2021","journal-title":"Eur Heart J Case Rep"},{"key":"B232","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1016\/j.jaccao.2020.10.013","article-title":"Immune checkpoint inhibitor-associated myocarditis with persistent troponin elevation despite Abatacept and prolonged immunosuppression","volume":"2","author":"Liu","year":"2020","journal-title":"JACC CardioOncol"},{"key":"B233","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s12978-024-01847-5","article-title":"Is a search for game changers preventing US from focusing on the necessary tasks of systems strengthening and norm change to facilitate adolescent contraceptive use?","volume":"21","author":"Lane","year":"2024","journal-title":"Reprod Health"},{"key":"B234","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.tcm.2020.05.008","article-title":"Update on acute myocarditis","volume":"31","author":"Ammirati","year":"2021","journal-title":"Trends Cardiovasc Med"},{"key":"B235","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-004699","article-title":"Reversal of immune-checkpoint inhibitor fulminant myocarditis using personalized-dose-adjusted Abatacept and ruxolitinib: proof of concept","volume":"10","author":"Nguyen","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B236","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1161\/CIRCULATIONAHA.124.073058","article-title":"Insights into recovery from acute fulminant myocarditis following successful treatment with ruxolitinib by comprehensive single-cell profiling","volume":"151","author":"Qin","year":"2025","journal-title":"Circulation"},{"key":"B237","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1161\/CIRCRESAHA.121.320704","article-title":"Myeloid cell PKM2 deletion enhances efferocytosis and reduces atherosclerosis","volume":"130","author":"Doddapattar","year":"2022","journal-title":"Circ Res"},{"key":"B238","doi-asserted-by":"publisher","first-page":"103970","DOI":"10.1016\/j.redox.2025.103970","article-title":"Rapamycin preserves cardiac function in autoimmune myocarditis by reprogramming Cxcl9(+) macrophages via the mTORC1-C\/EBPbeta-OSM axis","volume":"89","author":"Zhuang","year":"2026","journal-title":"Redox Biol"},{"key":"B239","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1161\/CIRCRESAHA.120.318629","article-title":"GSDMD-Mediated Cardiomyocyte pyroptosis promotes myocardial I\/R injury","volume":"129","author":"Shi","year":"2021","journal-title":"Circ Res"},{"key":"B240","doi-asserted-by":"publisher","first-page":"6640","DOI":"10.1038\/s41467-024-50996-5","article-title":"Gasdermin-E-mediated pyroptosis drives immune checkpoint inhibitor-associated myocarditis via cGAS-STING activation","volume":"15","author":"Sun","year":"2024","journal-title":"Nat Commun"},{"key":"B241","doi-asserted-by":"publisher","first-page":"300","DOI":"10.63032\/RFPY6607","article-title":"Tocilizumab in immune checkpoint inhibitor-induced myositis, myocarditis, and myasthenic syndrome: a rare case report and review of the literature","volume":"4","author":"Goncalves","year":"2025","journal-title":"ARP Rheumatol"},{"key":"B242","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1007\/s00262-024-03899-9","article-title":"Dual efficacy of tocilizumab in managing PD-1 inhibitors-induced myocardial inflammatory injury and suppressing tumor growth with PD-1 inhibitors: a preclinical study","volume":"74","author":"Chen","year":"2025","journal-title":"Cancer Immunol Immunother"},{"key":"B243","doi-asserted-by":"publisher","first-page":"106326","DOI":"10.1016\/j.envint.2020.106326","article-title":"Tracing surface and airborne SARS-CoV-2 RNA inside public buses and subway trains","volume":"147","author":"Moreno","year":"2021","journal-title":"Environ Int"},{"key":"B244","doi-asserted-by":"publisher","first-page":"9763","DOI":"10.1038\/s41598-024-60239-8","article-title":"Rho kinase inhibitor Y-27632 downregulates IL-1beta expression in mice with experimental autoimmune myocarditis","volume":"14","author":"Li","year":"2024","journal-title":"Sci Rep"},{"key":"B245","doi-asserted-by":"publisher","first-page":"4964","DOI":"10.1093\/eurheartj\/ehab618","article-title":"Cardiovascular immunotoxicities associated with immune checkpoint inhibitors: a safety meta-analysis","volume":"42","author":"Dolladille","year":"2021","journal-title":"Eur Heart J"},{"key":"B246","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1093\/eurheartj\/ehaa884","article-title":"The risk of cardiac events in patients receiving immune checkpoint inhibitors: a nationwide Danish study","volume":"42","author":"D\u2019Souza","year":"2021","journal-title":"Eur Heart J"},{"key":"B247","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: american society of clinical oncology clinical practice guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol"},{"key":"B248","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s40959-025-00300-1","article-title":"Incidence and survival outcomes of myocarditis and pericardial diseases associated with immune checkpoint inhibitor therapy","volume":"11","author":"Ozaki","year":"2025","journal-title":"Cardiooncology"},{"key":"B249","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s40959-024-00234-0","article-title":"Immune checkpoint inhibitors and pericardial disease: a systematic review","volume":"10","author":"Mudra","year":"2024","journal-title":"Cardiooncology"},{"key":"B250","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.amjcard.2026.02.010","article-title":"Atrial arrhythmia incidence and outcomes in patients treated with immune checkpoint inhibitor therapy","volume":"266","author":"Khan","year":"2026","journal-title":"Am J Cardiol"},{"key":"B251","doi-asserted-by":"publisher","DOI":"10.1093\/ehjci\/ehaa946.3488","article-title":"The risk of sudden cardiac death or ventricular arrhythmias on immune checkpoint inhibitors","volume":"41","author":"Mirabel","year":"2020","journal-title":"Eur Heart J"},{"key":"B252","doi-asserted-by":"publisher","first-page":"101390","DOI":"10.1016\/j.rmcr.2021.101390","article-title":"Immunotherapy-associated complete heart block in a patient with NSCLC: a case report and literature review","volume":"33","author":"Vartanov","year":"2021","journal-title":"Respir Med Case Rep"},{"key":"B253","article-title":"Arrhythmias","volume-title":"StatPearls, StatPearls Publishing Copyright \u00a9 2026","author":"Desai","year":"2026"},{"key":"B254","doi-asserted-by":"publisher","first-page":"103187","DOI":"10.1016\/j.jaccas.2024.103187","article-title":"Pacing solutions for immune checkpoint myocarditis and associated conduction disorders","volume":"30","author":"Palaskas","year":"2025","journal-title":"JACC Case Rep"},{"key":"B255","doi-asserted-by":"publisher","first-page":"152440","DOI":"10.1016\/j.semarthrit.2024.152440","article-title":"A scoping review of vasculitis as an immune-related adverse event from checkpoint inhibitor therapy of cancer: unraveling the complexities at the intersection of immunology and vascular pathology","volume":"66","author":"Lee","year":"2024","journal-title":"Semin Arthritis Rheum"},{"key":"B256","doi-asserted-by":"publisher","first-page":"3685","DOI":"10.1093\/rheumatology\/keae711","article-title":"Immune checkpoint inhibitors-associated vasculitis: a heterogeneous condition with possible severe disease course","volume":"64","author":"Chanson","year":"2025","journal-title":"Rheumatology (Oxford)"},{"key":"B257","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/BOR.0000000000000916","article-title":"2022 American college of rheumatology\/European alliance of associations for rheumatology classification criteria sets for three types of antineutrophilic cytoplasmic antibody-associated vasculitis","volume":"35","author":"Yazici","year":"2023","journal-title":"Curr Opin Rheumatol"},{"key":"B258","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1002\/acr.24634","article-title":"2021 American college of rheumatology\/vasculitis foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis","volume":"73","author":"Chung","year":"2021","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"B259","doi-asserted-by":"publisher","first-page":"4546","DOI":"10.1093\/rheumatology\/keaf172","article-title":"Immune checkpoint inhibitors-induced large vessel vasculitis: clinical characteristics and management from a European multicentre study","volume":"64","author":"Cottu","year":"2025","journal-title":"Rheumatology (Oxford)"},{"key":"B260","doi-asserted-by":"publisher","first-page":"e041925","DOI":"10.1161\/JAHA.125.041925","article-title":"Immune checkpoint inhibitors, atherosclerotic cardiovascular events, and plaque progression among women with cancer","volume":"15","author":"Suero-Abreu","year":"2026","journal-title":"J Am Heart Assoc"},{"key":"B261","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13184606","article-title":"Thrombotic complications associated with immune checkpoint inhibitors","volume":"13","author":"Wang","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B262","doi-asserted-by":"publisher","first-page":"e1154","DOI":"10.1161\/CIR.0000000000001457","article-title":"2026 ACC\/AHA\/AACVPR\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of dyslipidemia: a report of the American College of Cardiology\/American Heart Association joint committee on clinical practice Guidelines","volume":"153","author":"Blumenthal","year":"2026","journal-title":"Circulation"},{"key":"B263","doi-asserted-by":"publisher","first-page":"e9","DOI":"10.1161\/CIR.0000000000001168","article-title":"2023 AHA\/ACC\/ACCP\/ASPC\/NLA\/PCNA guideline for the management of patients with chronic coronary disease: a report of the American Heart Association\/American College of Cardiology joint committee on clinical practice guidelines","volume":"148","author":"Virani","year":"2023","journal-title":"Circulation"},{"key":"B264","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002916","article-title":"Immune checkpoint inhibitor treatment and atherosclerotic cardiovascular disease: an emerging clinical problem","volume":"9","author":"Poels","year":"2021","journal-title":"J Immunother Cancer"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1872588\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T10:35:22Z","timestamp":1785321322000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1872588\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,29]]},"references-count":264,"alternative-id":["10.3389\/fcvm.2026.1872588"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2026.1872588","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,29]]},"article-number":"1872588"}}